Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

This review discusses the role of androgens in male sexual differentiation and characteristics and reports no new clinical results; it emphasizes the androgen dependence of male pattern scalp hair loss.

This review describes the use of carbon dioxide for aesthetic treatments like skin rejuvenation and scar reduction but does not present new clinical findings.

Finasteride may decrease semen quality but not harm sperm production, and stopping the drug can improve semen quality; hyperprolactinemia can cause infertility but is treatable with medication.

This review discusses the classification and treatment of ejaculatory dysfunction, outlining both pharmacotherapy and behavioral therapy as primary interventions, but does not present new clinical findings.

The document discusses male and female pattern hair loss, its diagnosis methods, FDA-approved treatments like finasteride and minoxidil, their side effects, and the role of lifestyle changes.

This case report describes an atypical postfinasteride syndrome in a patient treated with both dutasteride and finasteride for androgenic alopecia, highlighting its multisystem involvement and irreversible nature.

This commentary reviews the post-Finasteride syndrome and argues that while the condition's validity is debated, comprehensive guidelines are needed to address related risks and treatment options; it reports no new clinical results.

This study reports that finasteride can effectively treat androgenic alopecia and may reduce prostate cancer risk by 25% in men with risk factors.

This special issue contains abstracts from the ASA 40th Annual Meeting, providing an overview of various studies without reporting new primary results.

This study found that men with early-onset androgenetic alopecia and certain risk factors may have worse gonadal steroidogenesis and an increased likelihood of developing gonadal dysfunction, suggesting a male equivalent of polycystic ovarian syndrome.

In this study, 19 patients treated with finasteride for androgenetic alopecia developed moderate to severe depression, which resolved after stopping the medication, suggesting an association between finasteride and mood disturbances.

This study found that men with androgenetic alopecia treated with pumpkin seed oil for 24 weeks experienced a notable 40% increase in hair count compared to a 10% increase with a placebo.

Saw palmetto extract can block the enzyme that converts testosterone in pig prostate cells.

Treatments for hair loss include hormone modifiers, minoxidil, and hair transplant surgery.

AGA is a genetic, hormonal hair loss treated with finasteride, minoxidil, and supplements, but new compounds are being developed.

This study concluded that thiocyanate promotes new cell formation and hair growth in animals and humans, with therapeutic effects seen in 51% of human alopecia areata cases after treatment, attributed to diverse biological mechanisms.

This review analyzes existing literature on prognostic factors for renal cell carcinoma, highlighting the need for continuous updates of prognostic models to reflect advancement in molecular pathway knowledge and targeted therapies.

The document concludes that accurate diagnosis of male and female gonadal disorders is crucial for effective treatment and better patient outcomes.

This article presents guidelines developed by a multidisciplinary expert panel for the care of adolescent transgender and non-binary individuals with gender dysphoria, emphasizing individualized, affirmative care to enhance well-being and quality of life.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.

In this study, 96% of men with persistent sexual side effects from finasteride reported continued dysfunction after discontinuation, suggesting these effects may endure long-term.

This article reviews the effects of various medications on male fertility, noting that while commonly used drugs can mostly have reversible impacts, conclusive human evidence remains limited.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

In this study, treatment with 1 mg of finasteride was associated with stable sexual function, suggesting that sexual side effects may be less common than indicated in clinical trials.

This study found that sexual and erectile function in men taking finasteride 1 mg did not significantly differ from age-matched controls, suggesting sexual side effects may be less common than previously reported.

This review summarizes preclinical and clinical information on herbal products for hair loss treatment, highlighting their mechanisms, follicular penetration, and potential side effects, suggesting they may offer alternatives to synthetic drugs with fewer side effects.

This study found that finasteride use for androgenetic alopecia was not associated with increased sexual dysfunction compared to an age-matched control group.

This review discusses sexual side effects in men with androgenic alopecia treated with 5-alpha reductase inhibitors and reports no new clinical findings.